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It is a well known fact that light emitted at a specific wavelength induces fluorescence in the
human body. This kind of fluorescence is called autofluorescence. The application of
autofluorescence diagnosis, on the other hand, is a more complicated system designed to
detect faint autofluorescence inherent in tissues/cells.We have adopted this autofluorescence
diagnosis method and developed a new autofluorescence endoscope imaging system called
the SAFE-1000. Normal mucosa emitting autofluorescence appears green on the monitor,
while abnormal mucosa shows a dark image caused by the lack of autofluorescence.
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1. INTRODUCTION
Endoscopic application of fluorescence for medical
detection of carcinoma has recently attracted con-
siderable attention. These spectroscopic techniques
can be classified into two basic types. One method is
called photodynamic diagnosis (PDD) [1,2,3] using
chemicals called photosensitizers that react to
various wavelengths of light. The other method is
autofluorescence diagnosis, hereafter referred to as
AFD, employing inherent tissue/mucosal auto-
fluorescence without the use of additional photo-
sensitizers.
PDD using tumor-affinitive photosensitizers is
the easier of the two techniques to apply. However,
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after intravenous administration of these chemi-
cal photosensitizers, a patient must remain in a
darkened environment until these light sensitive
chemicals have metabolized to a safe level. Actual
diagnosis via this method is somewhatmore difficult
due to the fact that fluorescence from the photo-
sensitizers interferes with the autofluorescence from
normal mucosa.
The application of AFD, on the other hand, is a
more complicated system designed to detect faint
autofluorescence inherent in tissues/cells. Since it
does not require the use of any photosensitizers, it
produces fewer side effects. Furthermore, it can be
performed in conjunction with conventional endo-
scopy. With safety concerns being the primary66 R. ADACHI et al.
factor, Asahi Optical Co., Ltd. has adopted this
AFDmethod and developed anew autofluorescence
endoscope imaging system called the SAFE-1000.
It is a well known fact that light emitted at a spe-
cific wavelength induces fluorescence in the human
body [3-9]. This kind of fluorescence is called
autofluorescence. Typically, a greater amount of
autofluorescene occurs with normal mucosa and
little fluorescene is exhibited by abnormal tissue.
Applying this same principle, Pentax has developed
a new autofluorescence endoscope imaging system
(Pentax SAFE-1000) without the application ofany
photosensitizing agents or use ofany laser.
By utilizing the same white light used in conven-
tional endoscopy through a pass filter that allows
passage of only specific wavelengths, the SAFE-
1000 collects blue light and delivers it endoscopi-
cally to mucosa to excite tissue autofluorescence. By
detecting and amplifying the faint autofluorescence
at a green wavelength from normal mucosa, a highly
sensitive video camera incorporated into the SAFE-
1000 can show the intensified green autofluorescent
image on a color monitor. However, for abnormal
tissue, the autofluorescence at the green wavelength
is significantly diminished, making it appear dark
on the video monitor. It can then be easily dis-
tinguished from the more intense autofluorescence
obtained from normal mucosa [2].
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FIGURE The overproduction of lactic acid through
glycolysis.
2. EXPERIMENTAL MODEL
Otto Warburg was a German biochemist who
discovered that there are considerable biochemical
differences between normal cells and cancer cells
[10]. For instance, he found that cancer cells pro-
duce more lactic acid than normal cells. This phe-
nomenon was confirmed both in vivo and in vitro
studies. Several investigations have been performed
on the overproduction by cancerous cell of lactic
acid, called the Warburg effect. Though the entire
process has not been completely defined, it has been
confirmed that this overproduction (oflactic acid) is
generated by glucose through a glycolysis pathway
(Fig. 1).
This increase in the overproduction of lactic acid
through glycolysis is due not so much to decreased
enzymatic action but to an increase in fermenting
activity. The fact that tumors consumemore glucose
than is usually required for normal growth indicates
that there is some malfunction in the mechanism at
which the cells control the speed of absorption of
glucose. It has actually been confirmed that the
cellular absorption speed of glucose is increased in
abnormal cells.
The following common substances found in the
human body are known to exhibit tissue autofluo-
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TABLE Fluorescent substances in the human body
Fluorescent Exitation light Fluorescent
substance wavelength (nm) wavelength (nm)
Tryptophan 280 340
Collagen 325 380
Elastin 410 440
NADH 365 470
Flavin 440 520
Porphyrin 400 630, 690
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FIGURE 2 Fluorescence spectrum by changing the ratios of
FMN and lactic acid.
varies. Flavin and its derivatives such as FMN or
FAD are enzymes or coenzymes that are widely
distributed throughout the human body and are
strongly associated with oxidation-reducti0n reac-
tions. Consequently, it is the molecular make-up
and their different metabolic processes which
produce the different relative densities of autofluo-
rescent and non-autofluorescent substances. This
seems to be one of the factors that would then
contribute to the different intensities in autofluo-
rescence inherent in various tissues. Moreover, it is a
well-known fact that blood flow increases in tumors
and cancerous tissues. Blood can be considered as a
non-autofluorescent substance in this case, because
it does not emit any autofluorescence at the ob-
served wavelength. Therefore, the increased blood
flow in tumors seems to be one of the primary
factors that could cause different intensities of
autofluorescence in various types of tissues. As a
result, it would appear that the SAFE-1000 could
aid in the detection of tumors by identifying met-
abolic differences, due to changes in cellular
abnormalities, via autofluorescence.
The substances that participate in the AFD are
not specified. In our study, we noted that when
the fluorescent substance is mixed with other
substances, the peak wavelength ofthe fluorescence
is not changed and is merely attenuated.
In this study, flavin and its derivative, flavin
mono nucleotide (FMN), have been selected
because flavin is associated with cellular/biochem-
ical metabolism and fluoresces in the green wave-
length. Based upon the Warburg effect, it is believed
that the different metabolic processes between nor-
mal mucosa and tumors might have some effects on
the spectral emission of their autofluorescene. We
have therefore developed the following experimen-
tal model (Fig. 2).
Figure 2 shows the fluorescence intensity exhib-
ited by several mixtures ofFMN and lactic acid due
simply to changing their proportions. At a molec-
ular level, FMN emits autofluorescence while lactic
acid does not. Depending upon the ratios in each
mixture, the fluorescence intensity of each mixture
3. PENTAX SAFE 1000 (A NEW
AUTOFLUORESCENCE ENDOSCOPE
IMAGING SYSTEM)
3.1. System Configuration
(1) Target Area: bronchial tubes.
(2) Equipment (Fig. 3):
(1) A bronchofiberscope (Pentax FB-18RX).
(2) An excitation light source (Pentax LX-
750AF) incorporating a 75W xenon lamp
and an excitation filter (EX filter). The EX
filter is automatically inserted to or
removed from the light path with the
changeover switch on the camera box.
Through the EX filter, the light source
delivers excitation blue light for antofluo-
rescence endoscopy. Without the filter, the
light source delivers white light for conven-
tional endoscopy.68 R. ADACHI et al.
(3) A video camera incorporating
-an endoscopic TV camera with a
410000-pixel 1/2" CCD;
a fluorescence TV camera;
light path changing optics (prism);
a fluorescence filter (FL filter);
animage intensifierwhich amplifies faint
fluorescence signal thousands of times;
a changeover witch on the TV camera
box. The switch changes the camera for
endoscopic or fluorescence use and
simultaneously inserts or removes the
EX filter to or from the light path;
-an image intensifier control switch
(AUTO FL CONTROL) on the TV
camera box. The switch can adjust the
brightness of fluorescence images.
(4) An image intensifier controller (Pentax
SAFE-1000c) which
-processes fluorescence images (frame
average addition of two-frame, four-
frame, eight-frame or live image with
the recursive filter);
changes the monochrome fluorescence
signal to the G signal;
adjusts the brightness and contrast ofthe
fluorescence images.
(5) Peripherals
a monitor;
a video cassette recorder;
a video printer.
3.2. Operation
(1) Conventional Endoscopy
By setting the changeover switch on the camera box
to "NORMAL", conventional endoscopic proce-
dure can be performed. The 75W xenon lamp in the
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FIGURE 4 The optical system of endoscopic autofluorescence imaging.
light source emits white light. Infrared light is
eliminated by the infrared (IR)cut filter. Bypassing
the EX filter, white light is transmitted via a light
guide to the target area. Images obtained with an
objective lens are transmitted via a fiberoptic image
guide back to the eyepiece of the endoscope and
guided through the prism to endoscopicTV camera.
(2) Autofluorescence Endoscopy
By setting the changeover switch on the camera box
to "AUTO FL", an autofluorescence endoscopic
procedure can be performed (Fig. 4). The white light
from the 75W xenon lamp is passed by the IR cut
filter and then by the EX filter which specifically
passes 420-450nm excitation light. The excitation
light is then transmitted via a light guide to the tar-
get area.
Images obtained with an objectivelens are trans-
mitted via a fiberoptic image guide back to the
eyepiece of the endoscope and guided through the
prism to the FL filter which specifically passes 490-
590nm fluorescence signal. The selected signal is
then amplified by the image intensifier thousands of
times, and by means of a video camera, appears
as fluorescent images on the monitor. Normal
mucosa emitting autofluorescence appears green
on the monitor, while abnormal mucosa shows a
dark image caused by the lack of autofluorescence,
which allows for easier recognition of carcinoma
in situ [11].
(3) Features
-Fluorescence observation without using any
photosensitizers;
-Detection of early cancers not superficially
visible;
Safer and less expensive without using lasers;
Possible to use conventional endoscopes;
A compact and space-saving system;
Easy to changeover between conventional and
fluorescent images, which enables moreaccurate
diagnosis.
4. CONCLUSION
The autofluorescence endoscope imaging system,
Pentax SAFE-1000, should aid physicians in the
ability to recognize areas of early cancer and70 R. ADACHI et al.
squamous metaplasia and in the detection of
precancerous lesions which cannot be identified by
conventional endoscopy. Compared to other fluo-
rescence techniques requiring photosensitizers, this
method is more appealing to and less traumatic for
patients.
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